RINVOQ disrupts the unrelenting itch and rash of
atopic dermatitis (AD) across a range of patient types1
INDICATION
RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable.
Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.
Select a patient below to hear about real RINVOQ patient stories
Nickie(age 35)
Interruptive Itch Day & Night
CLINICAL PRESENTATION
- Sleep impacted by itching throughout the night; uses extra sheets to help with peeling skin as a result of scratching
- Wears gloves due to burning, painful skin while cooking and washing dishes
- Puts cold, wet cloths on body to help with all-over itch
MEDICAL HISTORY
- Inadequately controlled on oral steroids; tried topicals
- Biologic naïve
- Diagnosed with moderate to severe AD
Logan(age 15)
Rash Constantly Caused Her to Cover Up
CLINICAL PRESENTATION
- Inflamed, flaky rash on arms and face; itch worsens at swim practice
- Mother noticed Logan's always wearing long sleeves to cover persistent rash
- Carries creams to help with skin appearance at school and theater practice
MEDICAL HISTORY
- Inadequately controlled on a biologic; tried topicals
- Diagnosed with moderate to severe AD
Helen(age 23)
Unrelenting Itch Impacting Daily Life
CLINICAL PRESENTATION
- Takes frequent breaks from workouts due to scratching
- Painful, itchy skin makes driving and sleep difficult (uses sleep aids)
- Inflamed rash made her not want to socialize as much
MEDICAL HISTORY
- Inadequately controlled on topical steroids and a biologic for 1 year
- Diagnosed with moderate to severe AD
Michael(age 60)
Dry, irritated, painful skin & intense itch
CLINICAL PRESENTATION
- Widespread irritated, painful skin with itch that's hard to ignore in social settings
- Wears gloves and wraps feet at work due to flaking, bleeding skin
- Rash on hands makes him more sensitive to touch
MEDICAL HISTORY
- Inadequately controlled on rounds of oral steroids; tried topicals, biologics, and steroid shots
- History of hypertension and diabetes
- Diagnosed with moderate to severe AD
Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with RINVOQ, particularly in patients with other cardiovascular (CV) risk factors. Patients should be informed about the symptoms of serious CV events and the steps to take if they occur.
Please see Important Safety Information, including BOXED WARNING on Serious Infections, Mortality, Malignancies, Major Adverse Cardiovascular Events, and Thrombosis, below.
PROPORTION OF PATIENTS WITH SKIN AND ITCH IMPROVEMENT AT WEEK 161
EASI 75 (Co-Primary Endpoint)
MEASURE UP 1
70%* (n=281) RINVOQ 15 mg
80%* (n=285) RINVOQ 30 mg
16% (n=281) placebo
MEASURE UP 2
60%* (n=276) RINVOQ 15 mg
73%* (n=282) RINVOQ 30 mg
13% (n=278) placebo
vIGA Score of 0/1 (Co-Primary Endpoint)
MEASURE UP 1
48%* (n=281) RINVOQ 15 mg
62%* (n=285) RINVOQ 30 mg
8% (n=281) placebo
MEASURE UP 2
39%* (n=276) RINVOQ 15 mg
52%* (n=282) RINVOQ 30 mg
5% (n=278) placebo
WP-NRS ≥4 (Ranked Secondary Endpoint)
MEASURE UP 1
52%* (n=274) RINVOQ 15 mg
60%* (n=280) RINVOQ 30 mg
12% (n=272) placebo
MEASURE UP 2
42%* (n=270) RINVOQ 15 mg
60%* (n=280) RINVOQ 30 mg
9% (n=274) placebo
STUDY DESIGN
MEASURE UP 1 (N=847) and MEASURE UP 2 (N=836) were 16-week, phase 3, multicenter, randomized, double-blind, placebo-controlled trials to evaluate the efficacy and safety of RINVOQ (15 mg or 30 mg) vs placebo in adult and pediatric (≥12 years of age) patients with refractory, moderate to severe atopic dermatitis who were candidates for systemic therapy. Patients were randomized 1:1:1 to receive RINVOQ 15 mg, RINVOQ 30 mg, or placebo.
*p≤0.001; RINVOQ vs placebo. NRI-C; ITT.
ITT=intent-to-treat; NRI-C=nonresponder imputation incorporating multiple imputation to handle missing data due to COVID-19; vIGA=Validated Investigator Global Assessment.
Many patients achieved EASI 75, vIGA 0/1, and an improvement in worst pruritus NRS ≥4 at Week 16. Click here to see Efficacy results.